ImmunityBio, Inc.
IBRX
Last
$10.53
Day
+6.3%
1y
+306.1%
5y
+0.7%
52w
-20.3%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0323d
EMA 21
9.16
EMA 50
8.57
EMA 200
7.17
20d high
-8.3%
5y high
-20.3%
5y range
78th
Positions held
Your positionsIBRX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
62
Hold
swing
Signal
Strong Buy
Target
$12.02
Stop
$8.85
Stop distance
15.9%
Target vs last
+14.2%
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
Bull case
- ImmunityBio operates in the biotechnology sector, which is experiencing significant growth due to increasing demand for innovative therapies and advancements in personalized medicine.
- Revenue increased by 16% compared to the prior quarter, reaching $51 million.
- The company has a strong gross margin of 99.4%, indicating effective cost management and product pricing.
Bear case
- The biotechnology industry is highly competitive, with many companies vying for market share and funding, which can strain resources and profitability.
- The operating margin remains negative at -120.4%, reflecting ongoing challenges in managing operational costs.
- ImmunityBio has a forward P/E ratio of -69.21, suggesting that investors are cautious about future earnings potential.
Fundamentals
| Market cap | $10.50B | Enterprise value | $11.37B | Trailing P/E | — | Forward P/E | -70.79 |
| PEG | — | Price / book | -9.97 | Beta | 0.03 | Dividend yield | 0.00% |
| Revenue growth | 93.9% | Earnings growth | — | Gross margin | 99.3% | Operating margin | -120.4% |
| Profit margin | 0.0% | ROE | — | ROA | -30.5% | Debt / equity | — |
| Current ratio | 5.72 | Free cash flow | -$186.56M | Analyst recommendation | strong_buy | Mean target | $12.75 |
| 52w high | $12.43 | 52w low | $1.95 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $51.2M | $44.2M | $38.3M | $32.1M | $26.4M |
| Op margin | -120.4% | -157.9% | -169.0% | -173.5% | -269.8% |
| Net income | -$230M | -$633M | -$61.9M | -$67.3M | -$92.6M |
| Gross margin | 99.4% | 99.5% | 99.0% | 99.4% | 99.5% |
| Gross profit | $50.9M | $44.0M | $37.9M | $31.9M | $26.3M |
| Operating income | -$61.7M | -$69.8M | -$64.7M | -$55.6M | -$71.3M |
- Revenue +16% vs prior quarter ($51M vs $44M).
- Gross margin 99.4% (was 99.5% prior quarter).
- Operating margin expanded to -120.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $113M | $14.7M | $0.6M | $0.2M | — |
| Op margin | -226.0% | -2334.2% | -58097.1% | -146090.4% | — |
| Net income | -$351M | -$414M | -$583M | -$417M | — |
| Gross margin | 99.3% | 100.0% | 100.0% | 100.0% | — |
| Gross profit | $113M | $14.7M | $0.6M | $0.2M | — |
| Operating income | -$256M | -$344M | -$361M | -$351M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
No headlines.
Price (daily)
Full chart · RSI · MACD · patternsIBRX · daily+6.7% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin